Acinetobacter baumannii has been designated as one of the six ESKAPE (Enterococcus, Staphylococcus, Klebsiella, Acinetobacter, Pseudomonas and Enterobacter) bacterial pathogens of greatest healthcare concern. While the organism is capable of producing an array of bacterial infections, A. baumannii bacteremia is a primary concern, resulting in mortality rates as high as 80% in certain patient populations.
Learn more about Efflux pumps and inhibitors of serum grown Acinetobacter baumannii
Antibiotics are agents that disrupt biological pathways or structural integrity in order to inhibit growth or kill bacterial pathogens. Beginning with the accidental discovery of penicillin in a contaminated experiment, they have become one of the most important developments in medicine.
Learn more about Identification of new antimicrobials active in physiologically relevant media.
Pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb), is a major global health concern, with roughly 8.7 million new cases diagnosed and 1.4 million deaths annually.
Learn more about Identifying new antimicrobial agents against Mycobacterium tuberculosis
The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species) cause the majority of U.S. healthcare-associated infections and can “escape” the therapeutic activity of current antibiotics, making the pursuit of new antimicrobial agents effective against these bacteria a high priority. In a high-throughput screen of a library of FDA-approved drugs against the ESKAPE pathogens, 38 compounds were newly reported to have bactericidal activity as indicated by the release of adenylate kinase (AK) from killed bacterial cells.
Learn more about Terfendine as a new S. aureus antibiotic